BACKGROUND: The factors comprising the delays in management of status epilepticus (SE) have not been systematically studied. METHODS: We studied retrospectively all adult patients (N = 82) diagnosed with SE in Helsinki University Central Hospital emergency room over a 2-year period. We analyzed prehospital, diagnostic, treatment, and treatment response delays based on medical records and quantitatively evaluated data availability and accuracy. RESULTS: SE manifested mostly without any warning symptoms, but every fifth case presented a pre-status period. Median prehospital delay was 2 h 4 min, including delays in emergency call, ambulance arrival, and patient transportation. Median delay of diagnosing SE was 2 h 10 min. EEG-based diagnosis was significantly delayed compared to clinical diagnosis. Median delay in recording EEG was 22 h 2 min. Median delay of the first medication was 35 min, and those of second- and third-stage medications were 3 h and 2 h 55 min, respectively. We applied stepwise definition for treatment response and counted delays accordingly: total convulsion period 5 h 52 min, Burst-suppression (BS) 17 h 30 min and return of consciousness 47 h 40 min. Median treatment period in intensive care unit was 2.7 days. Mortality over treatment period (median 7.7 days) was 8.5 %. No post-discharge follow-up was performed. CONCLUSION: Our study reveals unexpectedly and unacceptably long delays in SE management, stressing the importance of commitment to acknowledged management protocol. Delays in the treatment can and need to be shortened markedly by several strategies discussed in this article.
BACKGROUND: The factors comprising the delays in management of status epilepticus (SE) have not been systematically studied. METHODS: We studied retrospectively all adult patients (N = 82) diagnosed with SE in Helsinki University Central Hospital emergency room over a 2-year period. We analyzed prehospital, diagnostic, treatment, and treatment response delays based on medical records and quantitatively evaluated data availability and accuracy. RESULTS: SE manifested mostly without any warning symptoms, but every fifth case presented a pre-status period. Median prehospital delay was 2 h 4 min, including delays in emergency call, ambulance arrival, and patient transportation. Median delay of diagnosing SE was 2 h 10 min. EEG-based diagnosis was significantly delayed compared to clinical diagnosis. Median delay in recording EEG was 22 h 2 min. Median delay of the first medication was 35 min, and those of second- and third-stage medications were 3 h and 2 h 55 min, respectively. We applied stepwise definition for treatment response and counted delays accordingly: total convulsion period 5 h 52 min, Burst-suppression (BS) 17 h 30 min and return of consciousness 47 h 40 min. Median treatment period in intensive care unit was 2.7 days. Mortality over treatment period (median 7.7 days) was 8.5 %. No post-discharge follow-up was performed. CONCLUSION: Our study reveals unexpectedly and unacceptably long delays in SE management, stressing the importance of commitment to acknowledged management protocol. Delays in the treatment can and need to be shortened markedly by several strategies discussed in this article.
Authors: Vincent Navarro; Christelle Dagron; Sophie Demeret; Kim An; Lionel Lamhaut; Francis Bolgert; Michel Baulac; Pierre Carli Journal: Epilepsia Date: 2011-10 Impact factor: 5.864
Authors: Iván Sánchez Fernández; Nicholas S Abend; Satish Agadi; Sookee An; Ravindra Arya; James Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; William D Gaillard; Tracy A Glauser; Howard P Goodkin; Kush Kapur; Mohamad A Mikati; Katrina Peariso; Margie Ream; James Riviello; Robert C Tasker; Tobias Loddenkemper Journal: Neurology Date: 2015-05-06 Impact factor: 9.910
Authors: Mauricio F Villamar; Aaron M Cook; Chenlu Ke; Yan Xu; Jordan L Clay; Katelyn S Dolbec; Rachel Ward-Mitchell; Larry B Goldstein; Meriem Bensalem-Owen Journal: Neurol Clin Pract Date: 2018-12
Authors: Iván Sánchez Fernández; Michele C Jackson; Nicholas S Abend; Ravindra Arya; James N Brenton; Jessica L Carpenter; Kevin E Chapman; William D Gaillard; Marina Gaínza-Lein; Tracy A Glauser; Joshua L Goldstein; Howard P Goodkin; Ashley Helseth; Kush Kapur; Tiffani L McDonough; Mohamad A Mikati; Katrina Peariso; James Riviello; Robert C Tasker; Alexis A Topjian; Mark S Wainwright; Angus Wilfong; Korwyn Williams; Tobias Loddenkemper Journal: Neurology Date: 2016-12-23 Impact factor: 9.910
Authors: Anne-Mari Kantanen; Reetta Kälviäinen; Ilkka Parviainen; Marika Ala-Peijari; Tom Bäcklund; Juha Koskenkari; Ruut Laitio; Matti Reinikainen Journal: Crit Care Date: 2017-03-23 Impact factor: 9.097
Authors: I Sánchez Fernández; M Gaínza-Lein; N S Abend; A E Anderson; R Arya; J N Brenton; J L Carpenter; K E Chapman; J Clark; W D Gaillard; T A Glauser; J L Goldstein; H P Goodkin; A R Helseth; M C Jackson; K Kapur; Y-C Lai; T L McDonough; M A Mikati; A Nayak; K Peariso; J J Riviello; R C Tasker; D Tchapyjnikov; A A Topjian; M S Wainwright; A Wilfong; K Williams; T Loddenkemper Journal: Neurology Date: 2018-04-11 Impact factor: 9.910
Authors: Christoph Kellinghaus; Nicolas Lang; Andrea O Rossetti; Stephan Rüegg; Christian Tilz; Eugen Trinka; Iris Unterberger; Zeljko Uzelac; Felix Rosenow Journal: BMC Neurol Date: 2015-11-10 Impact factor: 2.474